Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Licenses Molecular Modeling Tech to Axxima

NEW YORK, June 19 - Accelrys has licensed its molecular-modeling technology, including the LigandFit software, to Axxima Pharmaceuticals for three years, the companies said today.


Axxima will use the molecular-modeling technology to target infectious diseases, including HIV, hepatitis C, and tuberculosis.

According to Accelrys, a wholly owned subsidiary of drug maker Pharmacopeia, LigandFit calculates the likelihood that a compound might react to protein targets.

Financial details were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.